Clinical trials: Diabetic Retinopathy

Diabetic Retinopathy

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

• Terminated
• Age: 18 years and older
• Phase 2
• Results posted

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).

Trial name

NCT05038020

Testing

AKST4290

Where

17 sites in United States

Volunteers

3 people

Sponsor

Alkahest, Inc.